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P rogrammed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors are cur-
rently the standard treatments for advanced NSCLC.  
Unlike conventional therapies,  immune checkpoint 
inhibitors (ICIs) such as PD-1/PD-L1 inhibitors some-
times induce atypical tumor responses including pseu-
doprogression and hyperprogressive disease (HPD).  
HPD is defined as a greater than two-fold increase in the 
tumor growth rate (TGR) of patients exhibiting disease 
progression [1 , 2].  HPD is caused not only by PD-1/
PD-L1 inhibitors but also,  less frequently,  by cytotoxic 
T lymphocyte associated antigen-4 (CTLA-4) inhibitors 
[3].  HPD is usually observed soon after prescription of 
immune checkpoint inhibitors [4]; to the best of our 
knowledge,  there has been no report on late-onset 
HPD.  We here report a case of late-onset rapid disease 
progression of advanced NSCLC at 5 months after ces-
sation of pembrolizumab; the disease course was thus 
distinct from conventional HPD.
Case
A male in the sixth decade of life was diagnosed with 
advanced pulmonary adenocarcinoma; the PD-L1 
tumor proportion score was 5%.  The progression rate 
was relatively mild; little progression was evident for 2 
months prior to treatment commencement. Pembrolizumab 
was prescribed as a second-line treatment following 
platinum doublet chemotherapy.  This significantly 
inhibited tumor growth for 11 months,  despite a 
3-month cessation of therapy because of immune-re-
lated adverse events (irAEs).  Then,  sternal and verte-
bral metastases developed.  Docetaxel was administered 
as a third-line therapy for 4 months; the pleural effu-
sion increased slightly and a small liver metastasis 
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We report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor.  A male was diag-
nosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment.  He received 
pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a 
slight increase in pleural effusion.  At the time of progression to docetaxel,  he commenced prednisolone 
because of immune-system-related diarrhea.  After that,  his general condition rapidly worsened with severe 
fatigue and hypoxia.  Computed tomography revealed a massive increase of pleural effusion and replacement of 
almost the entire liver with cancer over a period of 5 weeks.
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developed.  Just prior to docetaxel cessation,  he com-
menced oral prednisolone because of sustained immune 
system-related grade 2 diarrhea over 1 month in dura-
tion.  Although the diarrhea disappeared within a few 
days of prednisolone prescription,  his general condition 
rapidly worsened,  accompanied by severe fatigue,  and 
he underwent emergency hospitalization because of 
hypoxia.  Contrast-enhanced computed tomography 
showed that the pleural effusion had increased mas-
sively and almost the entire liver was replaced with 
cancer over 5 weeks; the progression rate had been 
relatively slow prior to prednisolone commencement 
(Fig. 1 and Fig. 2).  Pleurocentesis revealed a class V 
adenocarcinoma,  confirming that progression was 
attributable to lung cancer.
Discussion
We experienced a case of rapid disease progression 
of advanced NSCLC 5 months after cessation of pem-
brolizumab.  The disease course seemed to accelerate 
greatly (considering the prior progression rate) (Fig. 2);  
we diagnosed this as HPD caused by prior pembroli-
zumab.  Our case differs from conventional HPD 
patients in two ways.  One is that HPD developed after 
pembrolizumab cessation,  rather than during treat-
ment.  PD-1 inhibitors bind to lymphocytes for at least 
several months after drug cessation [5],  and may thus 
exert various effects long-term.  Prior to HPD develop-
ment,  our patient developed sustained diarrhea caused 
by irAEs,  and required steroid therapy,  suggesting that 
pembrolizumab remained in the body for a long time 
after drug cessation.  The other unique feature of our 
current case is that the patient initially responded to 
pembrolizumab before developing HPD.  All previously 
reported HPD cases exhibited rapid progression in the 
absence of any response to PD-1/PD-L1 inhibitors.  
Although the precise mechanism of HPD remains 
unclear,  one hypothesis is that HPD may be caused by a 
change in polarization of immunosuppressive cells 
modulated by PD-1/PD-L1 inhibitors [6].  In our cur-
rent case,  disease progression seemed to accelerate after 
steroid therapy for diarrhea (Fig. 1).  Such therapy 
might have modulated immune cell polarization,  caus-
ing formerly immuno-activating cells to become immu-
nosuppressive.  We propose that steroid therapy runs a 
risk of triggering late-onset HPD phenomena.
In conclusion,  we experienced a case of rapid dis-
ease progression of advanced NSCLC 5 months after 
cessation of pembrolizumab.  We propose that this be 
considered a case of late-onset HPD after cessation of 
immune checkpoint therapy.
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Fig. 1　 Treatment progression and TGR.
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Fig. 2　 Computed tomography showing rapid tumor growth after initiation of steroid.
